Estimation of the utilities of attributes of intravenous iron infusion treatment for patients with iron-deficiency anemia: a conjoint analysis in Japan

References

• United Nations, World Health Organization. Iron deficiency anaemia: assessment, prevention, and control: a guide for programme managers. Geneva: world Health Organization; 2001.
   Google Scholar
• Achebe MO, Mandell E, Jolley K, et al. Pagophagia and restless legs syndrome are highly associated with iron deficiency and should be included in histories evaluating anemia. Am J Hematol. 2022 [cited 2022 Dec 12]; [3 p.]. DOI: 10.1002/ajh.26775.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Zanella S. Pica as a manifestation of iron deficiency. Expert Rev Hematol. 2016;9(11):1075–1080.
   PubMed Web of Science ®Google Scholar
• Allen RP, Auerbach S, Bahrain H, et al. The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. Am J Hematol. 2013;88(4):261–264.
   PubMed Web of Science ®Google Scholar
• Kassebaum NJ, GBD 2013 Anemia Collaborators. The global burden of anemia. Hematol Oncol Clin North Am. 2016;30(2):247–308.
   PubMed Web of Science ®Google Scholar
• Uchida T, Kawachi Y, Sakamoto Y[, et al. Prevalence and pathogenesis of iron deficiency in Japanese women (1981–1991). Rinsho Ketsueki. 1992;33(11):1661–1665.
   PubMedGoogle Scholar
• Ministry of Health, Labour and Welfare. The national health and nutrition survey in Japan. Tokyo: Ministry of Health, Labour and Welfare; 2019.
   Google Scholar
• Iimori S, Naito S, Noda Y, et al. Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: the CKD-ROUTE study. Nephrology. 2015;20(9):601–608.
   PubMed Web of Science ®Google Scholar
• Mansurova JA, Karazhanova LK. Independent predictors of adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention during hospitalization. Kardiologiia. 2018;58(12):22–29.
   PubMed Web of Science ®Google Scholar
• Rössler J, Schoenrath F, Seifert B, et al. Iron deficiency is associated with higher mortality in patients undergoing cardiac surgery: a prospective study. Br J Anaesth. 2020;124(1):25–34.
   PubMed Web of Science ®Google Scholar
• Ikuta K, Ito H, Takahashi K, et al. Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study. Int J Hematol. 2019;109(1):50–58.
   PubMed Web of Science ®Google Scholar
• Keating GM. Ferric carboxymaltose: a review of its use in iron deficiency. Drugs. 2015;75(1):101–127.
   PubMed Web of Science ®Google Scholar
• Injectafer [package insert]. American Regent, Inc.; 2022 [cited 2022 Dec 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203565Orig1s019lbl.pdf.
   Google Scholar
• Iwasaki K, Takeshima T, Tateyama M, et al. Utilization of intravenous iron preparations for iron deficiency anemia: a longitudinal study using a Japanese health insurance claims database with annual health check-ups in 2018–2021. Forthcoming ISPOR Europe 2022; 2022 Nov 6 − 9; Vienna, Austria and Virtual.
   Google Scholar
• Toblli J, Angerosa M. Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose. Drug Des Devel Ther. 2014;8:2475–2491.
   PubMed Web of Science ®Google Scholar
• Rund D. Intravenous iron: do we adequately understand the short- and long-term risks in clinical practice? Br J Haematol. 2021;193(3):466–480.
   PubMed Web of Science ®Google Scholar
• Higgins A, Barnett J, Meads C, et al. Does convenience matter in health care delivery? A systematic review of convenience-based aspects of process utility. Value Health. 2014;17(8):877–887.
   PubMed Web of Science ®Google Scholar
• Wu D, Zhang Y, Boegelund M, et al. Development of a diminishing marginal disutility model for intravenous iron infusions based on data from a time trade-off study in China. Virtual ISPOR Europe 2021; 2021 Nov 30 − Dec 3; Virtual.
   Google Scholar
• Stewart KD, Johnston JA, Matza LS, et al. Preference for pharmaceutical formulation and treatment process attributes. Patient Prefer Adherence. 2016;10:1385–1399.
   PubMed Web of Science ®Google Scholar
• Hixson-Wallace JA, Dotson JB, Blakey SA. Effect of regimen complexity on patient satisfaction and compliance with warfarin therapy. Clin Appl Thromb Hemost. 2001;7(1):33–37.
   PubMed Web of Science ®Google Scholar
• Shikiar R, Rentz AM. Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues. Value Health. 2004;7(2):204–215.
   PubMed Web of Science ®Google Scholar
• Matza LS, Stewart KD, Lloyd AJ, et al. Vignette-based utilities: usefulness, limitations, and methodological recommendations. Value Health. 2021;24(6):812–821.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. London: National Institute for Health and Care Excellence; 2013 (Process and methods (PMG9).
   Google Scholar
• Bien DR, Danner M, Vennedey V, et al. Patients’ preferences for outcome, process and cost attributes in cancer treatment: a systematic review of discrete choice experiments. Patient. 2017;10(5):553–565.
   PubMedGoogle Scholar
• Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health–a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403–413.
   PubMed Web of Science ®Google Scholar
• Fesin injection 40mg. Package insert. Nichi-iko Pharmaceutical Co., Ltd.; 2014 [cited 2022 Dec 12]. Available from: https://www.info.pmda.go.jp/go/pack/3222400A1058_1_03 (Japanese).
   Google Scholar
• Ferinject solution for injection/infusion 500mg. Package insert. Zeria Pharmaceutical Co., Ltd.; 2021 [cited 2022 Dec 12]. Available from: https://www.info.pmda.go.jp/go/pack/3222404A1021_1_03/ (Japanese).
   Google Scholar
• Ikuta K, Hanashi H, Hirai K, et al. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study. Int J Hematol. 2019;109(1):41–49.
   PubMed Web of Science ®Google Scholar
• Kawabata H, Tamura T, Tamai S, Study Group, et al. Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study. Int J Hematol. 2022;116(5):647–658.
   PubMed Web of Science ®Google Scholar
• Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare, and Ministry of Economy, Trade and Industry. Ethical guidelines for life science and medical research involving human subjects. Tokyo: ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare, and Ministry of Economy, Trade and Industry; 2021 (partial revision in 2022, Japanese).
   Google Scholar
• Qunibi WY, Martinez C, Smith M, et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26(5):1599–1607.
   PubMed Web of Science ®Google Scholar
• Anker SD, Comin Colet J, Filippatos G, FAIR-HF Trial Investigators, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436–2448.
   PubMed Web of Science ®Google Scholar
• Canning M, Grannell L. A stain on iron therapy. Aust Prescr. 2020;43(5):160–163.
   PubMed Web of Science ®Google Scholar
• Tebben PJ. Hypophosphatemia: a practical guide to evaluation and management. Endocr Pract. 2022;28(10):1091–1099.
   PubMed Web of Science ®Google Scholar